News

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

New financing will support the company's lead retinitis pigmentosa programme, among other projects

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic retinopathy

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

Hidden signs of systemic disease, including heart attacks, may first reveal themselves through visual symptoms or subtle patient cues in the exam chair.

Enhanced screenings and a unified registry could save vision and lives.

Consistent trends across prevalence, incidence, odds and time-to-event models suggest ocular mitochondrial disease may indicate neurodegenerative risk

Current applications and future outlook on integrating robotic technology in the operating room.

Real-time data analysis and intelligent automation help streamline key steps.

Robotic laser arcuate incisions reduce variability and residual astigmatism.

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.

Neurotech Pharmaceuticals performs the first ENCELTO procedure.

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries

New research findings reveal that increased physical activity significantly slows visual field loss in patients with glaucoma, highlighting exercise as a potential protective factor.

PA5108 is a rod-shaped, biodegradable microimplant designed to significantly reduce IOP in patients with primary open-angle glaucoma consistently over 6 months.

AAVB-039 is the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

Tirzepatide and semaglutide show favorable ocular safety compared to traditional weight loss formulations

NICE approves idebenone for Leber hereditary optic neuropathy, offering hope for vision restoration and improved quality of life for patients.